+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Combination Anti-diabetes Drugs Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4771900
  • Report
  • April 2019
  • Region: Global
  • 90 pages
  • Mordor Intelligence
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • Merck
  • Novo Nordisk
  • Sanofi
  • MORE
Market Overview

The diabetes population in the world is increasing continuously. This trend is mainly due to the changing lifestyle of the majority of the population. Most of the population have unhealthy lifestyles. The change in lifestyle is due to the economic and industrial development in recent times in most of the countries. For most of the population, sedentary lifestyles and seemingly endless fast-food options have replaced the traditional ways of work, travel, and cuisine, making way for the increase of diseases, such as diabetic. WHO projects that diabetes will be the seventh leading cause of death in 2030. In 2014, 8.5% of adults aged 18 years and older had diabetes. In 2015, diabetes was the direct cause of 1.6 million deaths and in 2012, high blood glucose was the cause of another 2.2 million deaths. It expected that this number would keep increasing shortly.

Scope of the Report

The market is segmented by category (oral combinations and insulin combinations), by segment (Janumet, Ryzodeg, Xultophy, and NovoMix), and Geography

Key Market Trends

Diabetes Patients Need More than One Drug to Control their Glycemic Level
  • Diabetes is considered to be a rich man disease, not only because of the cost of the drugs but also because of the number of medicines one must consume. Over the years, a large number of drug manufacturers has introduced combination drugs, thus making it more convenient for consumers.
  • These combination drugs have two or more active pharmaceutical ingredients, thus serving the purpose of two anti-diabetic drugs. The manufacturers have in the past started with essential oral medicines, such as Janumet and now have developed advanced insulin combinations, such as Ryzodeg and Xultophy.
  • Consumer preference for these drugs has increased considerably over time. The combination drugs market was valued 4.01 billion in 2018 and is expected to witness a CAGR of 10%, during the forecast period.
Ryzodeg is Expected to Record a CAGR of 23%
  • Ryzodeg is a combination of ultra-long-acting insulin degludec (basal) and rapid-acting prandial insulin aspart (bolus).
  • At present, consumers need to use both the basal and bolus insulin to manage their glucose levels, but Ryzodeg acts as a perfect substitute to bolus and basal insulin.
  • Ryzodeg serves the purpose of the two insulin’s, making it more convenient for consumers. Due to its unique combination, the market for the drug is expected to grow exponentially shortly.
  • Ryzodeg is available in close to 18 countries, but Novo Nordisk plans to increase its marketing and sales resources to improve the availability of the drug inadvertently.
Competitive Landscape
  • The combination anti-diabetes drugs market is highly consolidated. Novo Nordisk market share is expected to increase because of the launch of Xultophy and Ryzodeg in many other countries.
  • Nov 2017: Novo Nordisk Korea has launched diabetes treatment Ryzodeg in the Korean market. Ryzodeg is the first combination insulin injection made from a 70-30 ratio of two types of insulin- insulin degludec and insulin aspart.
Note: Product cover images may vary from those shown
2 of 4


  • Merck
  • Novo Nordisk
  • Sanofi
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry

5.1 BY Drug
5.1.1 Combination Drugs Insulin Combinations NovoMix (Biphasic Insulin Aspart) Ryzodeg (Insulin Degludec and Insulin Aspart) Xultophy (Insulin Degludec and Liraglutide) Oral Combination Janumet (Sitagliptin and Metformin HCl)
5.2 Geography
5.2.1 North America United States (Value and Volume 2012-2024) Canada (Value and Volume 2012-2024) Rest of North America (Value and Volume 2012-2024)
5.2.2 Europe France (Value and Volume 2012-2024) Germany (Value and Volume 2012-2024) Italy (Value and Volume 2012-2024) Spain (Value and Volume 2012-2024) United Kingdom (Value and Volume 2012-2024) Russia (Value and Volume 2012-2024) Rest of Europe (Value and Volume 2012-2024)
5.2.3 Latin America Mexico (Value and Volume 2012-2024) Brazil (Value and Volume 2012-2024) Rest of Latin America (Value and Volume 2012-2024)
5.2.4 Asia - Pacific Australia (Value and Volume 2012 - 2024) China (Value and Volume 2012-2024) India (Value and Volume 2012-2024) Indonesia (Value and Volume 2012-2024) Japan (Value and Volume 2012-2024) Malaysia (Value and Volume 2012-2024) Philippines (Value and Volume 2012-2024) South Korea (Value and Volume 2012-2024) Thailand (Value and Volume 2012-2024) Vietnam (Value and Volume 2012-2024) Rest of Asia - Pacific (Value and Volume 2012-2024)
5.2.5 Middle East & Africa Saudi Arabia (Value and Volume 2012-2024) Iran (Value and Volume 2012-2024) Egypt (Value and Volume 2012-2024) Oman (Value and Volume 2012-2024) South Africa (Value and Volume 2012-2024) Rest of Middle East & Africa (Value and Volume 2012-2024)

6.1 Type-1 Diabetes population (2012-2024)
6.2 Type-2 Diabetes population (2012-2024)

7.1 Company Profiles
7.1.1 Novo Nordisk
7.1.2 Merck
7.1.3 Sanofi

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Novo Nordisk
  • Merck
  • Sanofi
Note: Product cover images may vary from those shown